Synchron vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synchron pioneers the world's first endovascular BCI (Stentrode) enabling paralysis patients to control devices with thoughts; raised $200M Series D (Nov 2025) totaling $345M, Apple BCI-HID integration achieved.
About
Synchron is a neurotechnology company developing brain-computer interface (BCI) technology using a minimally invasive endovascular surgical approach. Unlike conventional BCIs that require open-brain surgery to implant electrode arrays directly on the cortex, Synchron's Stentrode device is delivered through a catheter inserted via the jugular vein and positioned in a blood vessel adjacent to the motor cortex — requiring no open neurosurgery and dramatically reducing patient risk and recovery time. The Stentrode detects neural signals associated with intended movement and translates them into digital commands, enabling individuals with severe paralysis — from ALS, stroke, or spinal cord injury — to control computers, smartphones, and other devices using thought alone.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.